Disease Progress Models

Diane R Mould PhD

Projections Research Inc Phoenixville PA

January 29, 2009

Motivations for Disease Progression Models

- Visualization of the time course of disease in treated and untreated conditions
- Simulation of
 - Future course of disease
 - Various disease interventions to evaluate treatment options
 - Clinical trial designs
- Framework for regulatory submissions

New Objectives for Clinical Trials

- In a confirmatory trial, the purpose of that trial is to test the null hypothesis.
 - Clinical trials usually focused on testing null hypothesis because there is an alternative model that can be accepted in place of the null model.
- Testing the null hypothesis is an easy question to answer robustly
 - Traditionally statistics has been focused on questions that are easy to answer but not necessarily on answering the right questions.
- "Far better an approximate answer to the right question, which is often vague, than an exact answer to the wrong question, which can always be made precise." - Tukey

New Objectives for Clinical Trials

- Developing an exposure response surface is not an easy question to answer but maybe it's the right question to ask
 - Usually requires assumptions which weakens the robustness of the answers.
 - Assumptions reduce inferential certainty because if the assumptions are wrong, then the model based conclusions are wrong.
 - It is the quality of the attendant assumptions, not their existence, that is the issue. A summary of the surface function, such as an average over the
 - response surface can provide robust answers to simpler questions.

 - The margins of a high dimensional surface are usually well estimated, even with modeling.
 If a model is used to address the right question, the answer will have uncertainty associated with that answer, but summarizing or integrating over that model in order to answer simpler questions can still provide robust answers.

Evaluating a Response Surface

During drug development patients can have different responses

- Differing sensitivity contributes to the variability (e.g. noise) in the outcome of the study. Impossible to study all combinations of doses or treatments by patient type Need to develop the dose response surface without data from every type of patient given every dose level and duration of therapy
- The time course of disease in the untreated patient is also variable
- Characterizing the time course of placebo response allows better evaluation of drug effect Clinical markers of outcome are inherently variable as well
- Residual error for HAMD is notable
- Residual error for HAMU is notable
 Repeated measures assessments are generally more able to evaluate the central trend of a response
 Model based evaluations provides a basis for developing exposure response surface by making scientifically valid assumptions

Evaluating a Response Surface

Models increase the amount of information recovered from a clinical trial.

- Information obtained from any scientific study can be detected based on the ratio of signal to noise.
- In any given study, the information is the total variation in the data, the signal is the variation due to identifiable causes such as differences in dose, and the noise is the residual or unexplained variation.
- Models increase information by turning noise into signal by providing a basis for explaining the variation

Clinical Pharmacology

Disease Progress + Drug Action*

*It also follows that "Drug Action" = Drug Effect + Placebo Effect

• The effect of a drug involves understanding the progression of the disease and the effect of placebo as well as the effect of administering a test drug


PKPD Models

- Pharmacokinetic (dose, concentration, time)
 - drug disposition in individuals & populations
 - disease state effects (renal & hepatic dysfunction)
 - intervention effects (hemodialysis)
 - concurrent medication effects
 - pharmacogenetic influences
- Pharmacodynamic (dose or concentration, effect, time)
 - physiologic & biomarkers
 - surrogate endpoints
 - clinical effects and endpoints

Disease Progression Model

Quantitative model that accounts for the time course of disease status, S(t):

- "Symptoms" measures of how a patient feels or functions ("clinical endpoints")
- "Signs" physiological or biological measurements of disease activity ("biomarkers")
 - "Surrogate Endpoints" (validated markers predictive of, or associated with Clinical Outcome)
 - predictive of, or associated with Clinical Outcome)
 "Outcomes" (measures of global disease status, such
 - as pre-defined progression or death)





Components of a Disease Progression Model

S(t) = Baseline + Natural History + Placebo + Active


- Baseline Disease State, So
- Natural History
- Placebo Response
- Active Treatment Response

Placebo Response

Placebo response is the change in disease progression in untreated patients who are randomized to receive placebo as treatment for their disease in a clinical trial

- Usually transient improvement in clinical status followed by relapse to pre-study status
- In depression trials, the placebo response may be at least partly due to the interaction and attention that
 - the enrolled patients receive regardless of treatment • The placebo response time course in depression trials appears to be somewhat dependent on study design - more intensive clinical visits usually result in greater placebo response that is more persistent


Placebo response tends to be variable both in magnitude and duration and is often more notable when the clinical status is evaluated subjectively






Model Building Process


- Talk to a Disease Specialist
- Draw pictures of time course of disease
- Translate into disease progress model
- Explain the models/parameters to the Specialist
- Ask Disease Specialist for advice on factors influencing parameters
- Translate into models with appropriate parameters and covariates















Handling Pharmacokinetic Data for Disease Progress Models

- Use actual measured concentrations
- This is easy to do
- Use a "Link" model to create a lag between observed concentrations and observed effect
 - This is more "real" as the time course for change in disease status is usually not the same as the time course of the drug










Tacrine Treatment of Alzheimer's Disease


- Baseline Disease State: So
- Natural History: $S_0 + \alpha \cdot t$

Holford & Peace, Proc Natl Acad Sci 89 (1992):11466-11470


- Placebo Response: $\beta_{p} \cdot C_{e,p}(t)$
- Active Treatment Response: $\beta_a \cdot C_{e,A}(t)$





























Asymptotic Progression Models


- Useful if the marker of disease progression has
- a natural limit (0 or some other value)
- Zero Asymptote (S₀, k_{prog})
 Spontaneous recovery or return to a 0 value of
 - disease progression marker
 - Several functions used to describe
 - Exponential • Emax functions
- Non-Zero Asymptote (S₀, S_{ss}, k_{prog})
 Progression to maximal or "burned out" state (S_{ss})
 - Several functions used to describe
 - Emax functions
 - Growth functions

Dealing with Asymptotic Functions


- Both zero and nonzero asymptotic models can be altered to include
- Offset Pattern
- Slope Pattern
- Both Offset and Slope Patterns
- Selection of the function depends on nature of the marker of disease progression being evaluated






































































Gompertz Growth Function
Models

$$\frac{dRs}{dt} = K_{RS} \bullet Rr + \beta \bullet Rs \bullet (\beta_{max} - Rs) - \left[K_{SR} + \left(1 + \frac{E \max \bullet C_{e,A}}{EC50 + C_{e,A}}\right) \bullet K_{SO}\right] \bullet Rs$$

$$\frac{dRr}{dt} = K_{SR} \bullet Rs - K_{RS} \bullet Rr$$
Describes the Formation of Two Responses: Sensitive (Rs) and Resistant (Rr)

Defines a Maximal Response Drug Effect is Delayed via Link Model and Limited via Emax Model





Using Survival Functions to Describe Disease Progress Empirical means of evaluating the

- Empirical means of evaluating the relationship between the drug effect and the time course of disease progress
- · Links the pharmacodynamics to measurement of outcome

Survival Function

- S(†) = P(T > †)
- Monotone, Decreasing Function
- Survival is 1 at Time=0 and 0 as Time Approaches Infinity.
- The Rate of Decline Varies According to Risk of Experiencing an Event
- Survival is Defined as

 $S(t) = \exp(-H(t))$

Hazard Functions

- Hazard Functions Define the Rate of Occurrence of An Event
- Instantaneous Progression
- PKPD Model Acts on Hazard Function
- Cumulative Hazard is the Integral of the Hazard Over a Pre-Defined Period of Time
- Describes the Risk
- Translates Pharmacodynamic Response into a Useful Measure of Outcome
 - Assessment of Likely Benefit or Adverse Event
 - Comparison With Existing Therapy


Hazard Functions

Define "T" as Time To Specified Event (Fever, Infection, Sepsis following chemotherapy)


- T is Continuous (i.e. time)
- T is Characterized by:
 - Hazard: Rate of Occurrence of Event
 - Cumulative Hazard or Risk
 - Survival: Probability of Event NOT Occurring Before Time = t

Hazard Functions


- Hazard is Assumed to be a Continuous Function
- Can be Function of Biomarkers (e.g. Neutrophil Count)
- Hazard Functions can be Adapted for Any Clinical Endpoints Evaluated at Fixed Time Points (e.g. During Chemotherapy Cycle)
- The Hazard Function is Integrated Over Time to Yield Cumulative Probability of Experiencing an Event by a Specified Time (Risk).













Disease Progress Models

- Alzheimer's Disease
- Linear: Drug effects symptomaticDiabetic Neuropathy
- Linear: Drug effect both?
 Parkinson's Disease
- Asymptotic: Drug effect both?Osteoporosis
 - Inhibition of Bone Loss (estrogen)
- In most cases, the functions used to describe the trajectory of the disease marker are empirical. Whenever possible, mechanistic models should be used but for most diseases mechanisms are not always clearly understood

Summary

- Accounting for Disease Progress is Important For the Analysis of Drug Effects
 - Better Able to Discern True Effect
 - Improves Reliability of Simulation Work
 - Developing New Drug Candidates
 - Visualize the Drug Use Better
 - Convert Data into Understanding!
- Issues Associated With Building Disease Progress Models
 - Lack of Available Data for Untreated Patients
 - Time Required to Collect Data
 - Variability Inherent in Data May Require Large Numbers of Subjects to Determine Parameters Accurately